# Teranode

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/teranode

- Industry: Software
- Headquarters: Westwood, US
- Website: www.teranode.com
- Total disclosed funding: $9.5M
- Latest round: Series B (Sep 11, 2005)
- Investors on record: 4

## About

Teranode Corp offers a real-time pharmaceutical intelligence platform, enabling precise data analysis for drug development. Their solutions target various stakeholders in the pharmaceutical ecosystem, enhancing decision-making through actionable insights.Founded in 2002 in Westwood, US, Teranode Corp specializes in pharmaceutical intelligence with a focus on analytical solutions. The company has successfully completed 4 deals and recently raised USD 0.90 mn in a VENTURE DEBT round, bringing its total funding to USD 9.50 mn. Joe Duncan serves as CEO, leading the company through its strategic initiatives.Teranode specializes in providing real-time pharmaceutical intelligence through its advanced analytical platform. The company's core offerings focus on the accurate and contextual analysis of both structured data and unstructured text, enabling clients to derive actionable insights at every stage of the drug development life cycle. By integrating data from numerous internal and external sources, Teranode assists pharmaceutical companies in streamlining their R&D processes, ensuring compliance, and enhancing decision-making. Their solutions cater primarily to pharmaceutical developers, research institutions, and regulatory agencies, empowering them to make informed decisions backed by reliable data analysis. Teranode's products are marketed in North America and Europe, targeting a diverse clientele that includes biopharmaceutical firms and academic research organizations.Teranode generates revenue through a subscription-based model, where clients pay for access to its comprehensive data analysis services. The structure of these transactions typically involves annual or multi-year agreements, allowing clients to utilize the platform's capabilities consistently over time. The company may also engage in strategic partnerships with pharmaceutical firms, enhancing the value of their offerings through collaborative integrations or tailored solutions. While specific pricing plans for individual services are not disclosed, the revenue model indicates a focus on long-term relationships with clients, fostering ongoing engagement and utilization of Teranode's analytical tools. The flagship offerings of the company are designed to support various stakeholders in the pharmaceutical ecosystem, ensuring that clients can navigate the complexities of drug development effectively.Teranode Corp has ceased operations. As such, there are no upcoming products or market expansions planned, and recent funding will not support future initiatives.

## Funding rounds

- Series B, Sep 11, 2005, $9.5M — Trident Capital, Ignition Partners, Cargill Ventures, WRF Capital

## Investors

- Trident Capital (https://capitalatlas.ai/funds/trident-capital) — Series B
- Ignition Partners (https://capitalatlas.ai/funds/ignition-partners) — Series B
- Cargill Ventures (https://capitalatlas.ai/funds/cargill-ventures) — Series B
- WRF Capital (https://capitalatlas.ai/funds/wrf-capital) — Series B